Jiudian Pharmaceutical signed a patent and technology transfer agreement for LPS/CD 14 dual-target spot polypeptide new drug with Zonsen PepLib Biotech in Changsha China on Feb 28, 2024.

The total transaction volume of the cooperation agreement is more than 560 million RMB, and the initial payment is 15 million RMB.

The polypeptide drug above-mentioned has the dual function of antibacterial and anti-inflammatory.

From this agreement, Jiudian Pharmaceutical have the exclusive rights to develop, produce and commercialize the above polypeptide drug candidates in the world. And we have the same rights in the field of cosmetic medicine and others.

It is a big step in the development of polypeptide drugs for Hunan Jiudian Pharmaceutical Co., Ltd.